Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trialYuemei Hu, Ningshao Xia, Xiaowen Hu et al.|Science Bulletin|2023Cited by 26
Long-term protection from naturally acquired immunity against hepatitis E virus reinfectionXiaohui Liu, Ningshao Xia, Ting Wu et al.|Nature Communications|2025Cited by 0